Abstract
Gangliosides are important cell surface molecules in tumors of the nervous system. Initially thought of particularly as diagnostic disease markers, the biological properties and in vivo roles of tumor gangliosides have been recognized more recently. The latter affect the formation and progression of tumors of many types, including neural tumors. This chapter focuses on a prominent and almost universal dynamic property of tumor cells, the rapid synthesis and shedding of gangliosides, and consequences on the host response to tumors. In contemporary terms, these effects are understood to be functional properties of tumor cells affecting normal cells in the tumor microenvironment. Some of the most comprehensive studies have been possible in the human neuroectodermal tumors, neuroblastomas, including first observations of the shedding and activities of human tumor gangliosides. Citing other selected examples from tumors of different types, the impact and mechanisms of action of tumor gangliosides in facilitating tumor formation and progression will be delineated, leading to consideration of clinical relevance and therapeutic implications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bergelson LD, Dyatlovitskaya EV, Klyuchareva TE, Kryukova EV, Lemenovskaya AF, Matveeva VA, et al. The role of glycosphingolipids in natural immunity. Gangliosides modulate the cytotoxicity of natural killer cells. Eur J Immunol. 1989;19(11):1979–83.
Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G, et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res. 2006;66(13):6816–25.
Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol. 2003;171(4):1676–83. Epub 2003/08/07.
Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 2005;65(12):5428–38. Epub 2005/06/17.
Chu JW, Sharom FJ. Gangliosides interact with interleukin-4 and inhibit interleukin-4-stimulated helper T-cell proliferation. Immunology. 1995;84(3):396–403.
Foulds L. Multiple etiologic factors in neoplastic development. Cancer Res. 1965;25(8):1339–47. Epub 1965/09/01.
Grayson G, Ladisch S. Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol. 1992;139(1):18–29. Epub 1992/01/01.
Gullino PM. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol. 1995;34(3):439–41. Epub 1995/01/01.
Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res. 1985;45(6):2405–14. Epub 1985/06/01.
Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56(23):5309–18. Epub 1996/12/01.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. Epub 2000/01/27.
Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci. 2003;995:151–61. Epub 2003/06/20.
Hettmer S, Malott C, Woods W, Ladisch S, Kaucic K. Biological stratification of human neuroblastoma by complex “B” pathway ganglioside expression. Cancer Res. 2003;63(21):7270–6. Epub 2003/11/13.
Kaucic K, Etue N, LaFleur B, Woods W, Ladisch S. Neuroblastomas of infancy exhibit a characteristic ganglioside pattern. Cancer. 2001;91(4):785–93. Epub 2001/03/10.
Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 1983;43(8):3808–13.
Ladisch S, Ulsh L, Gillard B, Wong C. Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. J Clin Invest. 1984;74(6):2074–81. Epub 1984/12/01.
Ladisch S, Gillard B. A solvent partition method for microscale ganglioside purification. Anal Biochem. 1985;146(1):220–31. Epub 1985/04/01.
Ladisch S, Wu ZL. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma. Lancet. 1985;1(8421):136–8. Epub 1985/01/19.
Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, et al. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer. 1987;39(1):73–6. Epub 1987/01/15.
Ladisch S, Sweeley CC, Becker H, Gage D. Aberrant fatty acyl alpha-hydroxylation in human neuroblastoma tumor gangliosides. J Biol Chem. 1989;264(20):12097–105. Epub 1989/07/15.
Ladisch S, Becker H, Ulsh L. Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim Biophys Acta. 1992;1125(2):180–8. Epub 1992/04/23.
Ladisch S, Li R, Olson E. Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc Natl Acad Sci U S A. 1994;91(5):1974–8. Epub 1994/03/01.
Ladisch S, Chang F, Li R, Cogen P, Johnson D. Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid. Cancer Lett. 1997;120(1):71–8.
Lang Z, Guerrera M, Li R, Ladisch S. Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. Biochem Biophys Res Commun. 2001;282(4):1031–7. Epub 2001/05/16.
Lee HC, Wondimu A, Liu Y, Ma JS, Radoja S, Ladisch S. Ganglioside inhibition of CD8+ T cell cytotoxicity: interference with lytic granule trafficking and exocytosis. J Immunol. 2012;189(7):3521–7. Epub 2012/09/08.
Li R, Gage D, McKallip R, Ladisch S. Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2. Glycoconj J. 1996;13(3):385–9.
Li R, Manela J, Kong Y, Ladisch S. Cellular gangliosides promote growth factor-induced proliferation of fibroblasts. J Biol Chem. 2000;275(44):34213–23. Epub 2000/06/22.
Li R, Liu Y, Ladisch S. Enhancement of epidermal growth factor signaling and activation of SRC kinase by gangliosides. J Biol Chem. 2001;276(46):42782–92. Epub 2001/09/06.
Li RX, Ladisch S. Shedding of human neuroblastoma gangliosides. Biochim Biophys Acta. 1991;1083(1):57–64. Epub 1991/04/24.
Liu Y, Li R, Ladisch S. Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J Biol Chem. 2004;279(35):36481–9. Epub 2004/06/25.
Liu Y, McCarthy J, Ladisch S. Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res. 2006;66(21):10408–14. Epub 2006/11/03.
Liu Y, Yan S, Wondimu A, Bob D, Weiss M, Sliwinski K, et al. Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth. Oncogene. 2010;29(22):3297–306. Epub 2010/03/23.
Liu Y, Wondimu A, Yan S, Bobb D, Ladisch S. Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis 2013. Epub 2013/10/30.
Manfredi MG, Lim S, Claffey KP, Seyfried TN. Gangliosides influence angiogenesis in an experimental mouse brain tumor. Cancer Res. 1999;59(20):5392–7. Epub 1999/10/28.
McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol. 1999;163(7):3718–26. Epub 1999/09/22.
Merritt WD, Der-Minassian V, Reaman GH. Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia. Leukemia. 1994;8(5):816–22.
Nakamura O, Ishihara E, Iwamori M, Nagai T, Matsutani M, Nomura K, et al. Lipid composition of human malignant brain tumors. No To shinkei. 1987;39(3):221–6. Epub 1987/03/01.
Nieto-Sampedro M, Valle-Argos B, Gomez-Nicola D, Fernandez-Mayoralas A, Nieto-Diaz M. Inhibitors of glioma growth that reveal the tumour to the immune system. Clin Med Insights Oncol. 2011;5:265–314. Epub 2011/11/16.
Peracoli MT, Montelli TC, Soares AM, Parise-Fortes MR, Alquati SA, Ueda A, et al. Immunological alterations in patients with primary tumors in central nervous system. Arq Neuropsiquiatr. 1999;57(3A):539–46. Epub 2000/02/10.
Portoukalian J, David MJ, Gain P, Richard M. Shedding of GD2 ganglioside in patients with retinoblastoma. Int J Cancer. 1993;53(6):948–51.
Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Santin AD, Bellone S, et al. Immunogenic gangliosides in human ovarian carcinoma. Biochem Biophys Res Commun. 2007;353(2):251–8.
Robb RJ. The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association. J Immunol. 1986;136(3):971–6.
Sawada M, Moriya S, Saito S, Shineha R, Satomi S, Yamori T, et al. Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int J Cancer. 2002;97(2):180–5. Epub 2002/01/05.
Schengrund CL, Repman MA, Shochat SJ. Ganglioside composition of human neuroblastomas. Correlation with prognosis. A Pediatric Oncology Group Study. Cancer. 1985;56(11):2640–6. Epub 1985/12/01.
Shen W, Ladisch S. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell Immunol. 2002;220(2):125–33. Epub 2003/03/27.
Shen W, Stone K, Jales A, Leitenberg D, Ladisch S. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol. 2008;180(7):4425–32. Epub 2008/03/21.
Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale Jr EM. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 2001;61(1):363–9. Epub 2001/02/24.
Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11(20):7234–42. Epub 2005/10/26.
Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood. 1990;75(7):1564–7. Epub 1990/04/01.
Wang J, Yu RK. Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro. Proc Natl Acad Sci U S A. 2013;110(47):19137–42. Epub 2013/11/08.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34. Epub 2010/10/01.
Zhou J, Shao H, Cox NR, Baker HJ, Ewald SJ. Gangliosides enhance apoptosis of thymocytes. Cell Immunol. 1998;183(2):90–8.
Conflicts of Interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ladisch, S., Liu, Y. (2014). Dynamic Aspects of Neural Tumor Gangliosides. In: Yu, R., Schengrund, CL. (eds) Glycobiology of the Nervous System. Advances in Neurobiology, vol 9. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1154-7_23
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1154-7_23
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1153-0
Online ISBN: 978-1-4939-1154-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)